Massive malawi trial aims to shield kids from typhoid
NCT ID NCT03299426
First seen May 15, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This large phase 3 trial is testing a typhoid conjugate vaccine (Vi-TCV) in 30,000 healthy children aged 9 months to 12 years in Malawi. Half get the typhoid vaccine, half get a meningitis vaccine for comparison. The goal is to see if the typhoid vaccine prevents blood-confirmed typhoid fever and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPHOID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Malawi Liverpool Wellcome Trust Clinical Research Programme, Queen Elizabeth Central Hospital College of Medicine
Blantyre, P.O. Box 30096, Malawi
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Typhoid conjugate vaccine (Vi-TCV)
What this could lead to
If it works, this vaccine could protect children in typhoid-prone areas from a serious bacterial infection, reducing illness and deaths.
What could go wrong
This is a large trial, but results may not apply to all regions. The vaccine may cause side effects like pain or fever, and its long-term protection is still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.